• Facebook
  • Instagram
  • Twitter

Get Support – Call 1-888-MITO-411

  • Shop
  • Events
  • Donate
  • Search
MitoAction

MitoAction

Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease

  • Mitochondrial Disease
    • About Mito
      • New Patient Kit
      • Types of Mitochondrial Diseases
      • Symptoms of Mito
      • Treatment for Mito
      • Diagnosing Mito
      • Mito FAQs
      • Mito in the News
    • Diagnosis & Care
      • Mitochondrial Disease Diagnosis
      • Find a Mito Doctor
      • Mito Disease Treatment
      • Mito Cocktail
      • Clinical Trials & Studies
    • Day to Day with Mito
      • Mito Life Hacks
      • Mito Resources
      • Living with Mitochondrial Disease
      • Care Coordination & Management
      • Managing Your Energy
      • Traveling with Mito
    • For Medical Professionals
      • Mitochondrial Care Network
      • Monthly Expert Series
  • Fatty Acid Oxidation Disorders
    • About FAODs
      • Types of FAODs
      • Symptoms of FAODs
      • Diagnosing FAODs
      • Treatment for FAODs
    • FAOD Programs & Support
      • New Patient Kit
      • FAOD Support Calls
      • FAOD Experts Series
      • International Metabolic Conference
    • Day to Day with FAOD
      • FAOD Resources
      • FAOD Life Hacks
  • Programs & Support
    • Patient & Family Support
      • Mito411
      • Support Calls
      • MitoAction Memories
      • MitoPlaydates
      • MitoSocials
      • Become a MitoChampion
      • Positive Peach Packages
      • Liney’s Lovies
    • MitoAction Programs
      • Dalia’s Wish
      • Matthew Harty Camper Fund & Scholarship
      • Marcel’s Way Family Fund
      • MitoArtisan’s Playtime
      • MitoSantas
      • MyMito App
    • Education
      • Monthly Expert Series
      • Wondering Wednesdays
      • Energy In Action Podcast
      • Energy 4 Education
      • Patient Education Forums
      • International Metabolic Conference
    • Planning & Preparation
      • Health Insurance
      • Disability Benefits
      • Mobility Devices
      • Vehicle Modification
      • Estate Planning
      • Medical Child Abuse
  • Join the Cause
    • Giving
      • Donate to MitoAction
      • Honor and Memorial Giving
      • Matching Gifts
      • Another Helping
      • Giving Tuesday
      • Shop for MitoAction
    • Events
      • Events Calendar
      • International Metabolic Conference
      • MitoAction Energy Walks
      • Sandra K. Russell Derby Day Benefit for Mito
      • Matthew Harty Camper Fund Events
    • Volunteer
      • Host a MitoSocial
      • Host a MitoPlaydate
      • Create a Fundraiser
      • Become a MitoChampion
      • Share Your Ideas
    • Raise Your Voice
      • Take Legislative Action
      • Mitochondrial Disease Awareness Week
      • Open Mito Mic & Art Show
      • MitoAction Memories
  • About MitoAction
    • Contact Us
    • Connect on Social
    • Our Team
    • Meet Our Partners
    • Newsletter Signup
  • Show Search

Edison Pharma’s Partnership Offers Hope for Mito Communuty

Print Friendly, PDF & Email

The nation’s leading mitochondrialRelated to the mitochondria. disease patient advocacy organizations have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd. of Japan. The Mitochondrial Disease Action Committee (MitoAction) and the United Mitochondrial Disease Foundation (UMDF) believe that the partnership between the two pharmaceutical companies is monumental for the mitochondrial disease patient community.

The partnership enables Edison to have the resources to bring drugs specifically created for pediatric mitochondrial disease patients, like EPI-743, to the marketplace. The partnership also enables both companies to research, develop, and build a pipeline containing 10 new drugs targeting various aspects of cellular energy metabolism. Those efforts will allow the two companies the ability to target adult neurological diseases that also directly impact the mitochondrial disease adult community.

“Not only does the partnership between Edison and Dainippon Sumitomo give us real hope for a treatment for mitochondrial disease in the foreseeable future, this alliance instantiates the field of ‘mitochondrial medicine,’” said Cristy Balcells, RN MSN, and Executive Director of MitoAction. “Our patients, patient community and separately Edison have been pioneering this concept. Today, our dream has become a reality. We believe the field of mitochondrial medicines will grow and establish itself as a standard medical and household term,” Balcells added.

“This is a huge victory for mitochondrial medicine,” said Charles A. Mohan, Jr., CEO/Executive Director of the UMDF.  “When a partnership of this magnitude is announced, it brings attention to the broader impact that finding treatments and cures for mitochondrial disease has on all of us,” Mohan said.

Mitochondrial dysfunctionThis is when mitochondria do not work as well as they should due to another disease or condition. Many conditions can lead to secondary dysfunction. is linked to many neurological diseases such as Parkinson’s, Alzheimer’s, ALS, and other diseases like diabetes and some cancers.

“Our expanded partnership with Dainippon Sumitomo Pharma codifies a common value system and vision for discovering and developing new drugs for patients suffering from diseases that share a common mitochondrial mechanism,” said Guy Miller, MD, PhD, Chairman, CEO, Edison Pharmaceuticals, Inc. “By combining efforts with DSP, we are able to scale our initial discoveries and therapeutic programs, and to begin to establish our commercial enterprise. This will start with EPI-743 currently being developed for children with a variety of rare mitochondrial diseases.”

As patient advocacy groups, UMDF and MitoAction have worked in a collaborative effort over the past five years to provide education and information about Edison’s EPI-743 and other novel therapeutics in development. Both organizations are grateful to the Edison team, specifically Guy Miller, for his dedication, inspiration, and transparency in providing information to, and receiving input from the mitochondrial disease patient community as he continues his mission toward providing the first approved mitochondrial disease drug.

Please join us for a teleconference with Edison Pharma to learn more about this alliance and ask questions.

Listen Now

Upcoming Events

View All
Jun 15
All day

Celebrate Father’s Day

Jun 17
8:30 pm

Our Space: A space for young adults with Mito and FAODs to connect and network

Jun 18
7:00 pm

MitoChampions Meeting

View Calendar

Expert Series

View All
There are no upcoming events.

Last Presentation

Expert Series: Serial Casting and Toe Walking
Presented April 25, 2025

P.O. Box 310
Novi, MI 48376
(888) 648-6228
info@mitoaction.org

  • Support
  • Resources
  • Donate to MitoAction
  • Events
  • Subscribe
©2025 MitoAction. All Rights Reserved.

Privacy Policy. Terms of Use.